Antineoplastic - Anaplastic Lymphoma Kinase (ALK) Inhibitors

Antineoplastic anaplastic lymphoma kinase (ALK) inhibitors are a targeted therapeutic class of small-molecule tyrosine kinase inhibitors designed to selectively block oncogenic ALK signaling Therapeutically, this class is primarily indicated for patients with locally advanced or metastatic non-small cell lung cancer harboring an ALK rearrangement

Antineoplastic anaplastic lymphoma kinase (ALK) inhibitors are a targeted therapeutic class of small-molecule tyrosine kinase inhibitors designed to selectively block oncogenic ALK signaling By binding to the ATP-binding pocket of the ALK receptor kinase, these agents disrupt constitutive phosphorylation and shut down downstream oncogenic cascades—such as the STAT3, AKT, and MAPK pathways—that promote malignant cell proliferation and survival

By binding to the ATP-binding pocket of the ALK receptor kinase, these agents disrupt constitutive phosphorylation and shut down downstream oncogenic cascades—such as the STAT3, AKT, and MAPK pathways—that promote malignant cell proliferation and survival

Therapeutically, this class is primarily indicated for patients with locally advanced or metastatic non-small cell lung cancer harboring an ALK rearrangement Select agents within the class also have approved roles or established utility in other ALK-driven malignancies, including relapsed or refractory systemic anaplastic large-cell lymphoma and unresectable inflammatory myofibroblastic tumors

Therapeutically, this class is primarily indicated for patients with locally advanced or metastatic non-small cell lung cancer harboring an ALK rearrangement